Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Live zoster vaccine confers limited protection during tofacitinib therapy

Key clinical point: Patients with RA given the live attenuated zoster vaccine (Zostavax) are still at risk for shingles during tofacitinib therapy.

Major finding: With 27-months’ follow-up, 5% of patients vaccinated before starting tofacitinib nonetheless developed herpes zoster.

Study details: An open-label, long-term extension study involving 100 patients with RA aged ≥50 years who were vaccinated before starting tofacitinib.

Disclosures: The study was sponsored by Pfizer. Dr. Winthrop disclosed consulting for AbbVie, Bristol-Myers Squibb, Eli Lilly, Galapagos, Gilead, Pfizer, and UCB and receiving grant/research support from Bristol-Myers Squibb. Two coauthors disclosed financial relationships with Pfizer and other pharmaceutical companies, and the other seven coauthors were employees and shareholders of Pfizer.

Citation:

Winthrop KL et al. Ann Rheum Dis. 2020 Mar 11. doi: 10.1136/annrheumdis-2019-216566.